Scarica l'app Stockscreener
36.06
0.22%
0.08
Dopo l'orario di chiusura:
36.13
0.07
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$35.98
Aprire:
$35.94
Volume 24 ore:
3.13M
Relative Volume:
0.90
Capitalizzazione di mercato:
$15.59B
Reddito:
$2.31B
Utile/perdita netta:
$1.66B
Rapporto P/E:
15.68
EPS:
2.3
Flusso di cassa netto:
$827.02M
1 W Prestazione:
-2.22%
1M Prestazione:
-1.66%
6M Prestazione:
+8.06%
1 anno Prestazione:
+26.44%
Intervallo 1D:
$35.48
$36.19
Intervallo di 1 settimana:
$35.48
$36.99
Portata 52W:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Confronta RPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.06 | 15.56B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.72B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 60.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 58.15B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 41.45B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Can swing trading help recover from Royalty Pharma plc lossesJuly 2025 EndofMonth & Reliable Price Action Trade Plans - Newser
Technical signs of recovery in Royalty Pharma plcJuly 2025 Setups & Free Accurate Trade Setup Notifications - Newser
Using data filters to optimize entry into Royalty Pharma plcBuy Signal & Community Verified Watchlist Alerts - Newser
Quant Tools Rank Royalty Pharma plc as High Risk High Reward getLinesFromResByArray error: size == 0 - 더경남뉴스
Signal strength of Royalty Pharma plc stock in tech scannersWeekly Trade Analysis & Reliable Volume Spike Trade Alerts - Newser
Best data tools to analyze Royalty Pharma plc stockTrade Volume Summary & Verified Swing Trading Watchlist - Newser
Royalty Pharma plc stock volume spike explainedPortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - Newser
Will Royalty Pharma plc benefit from macro trendsMarket Growth Summary & Expert Curated Trade Ideas - Newser
Is Royalty Pharma plc stock entering bullish territory2025 Key Highlights & AI Forecast for Swing Trade Picks - Newser
Northern Trust Corp Sells 354,172 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc stock outlook for YEARGlobal Markets & Free Reliable Trade Execution Plans - Newser
What’s next for Royalty Pharma plc stock priceJuly 2025 PreEarnings & Real-Time Volume Trigger Notifications - Newser
Royalty Pharma (NASDAQ:RPRX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
How to recover losses in Royalty Pharma plc stockJuly 2025 PostEarnings & Safe Entry Zone Tips - Newser
Analyzing Royalty Pharma plc with risk reward ratio chartsEntry Point & Free Community Consensus Stock Picks - Newser
Royalty Pharma PLC $RPRX Shares Acquired by Aberdeen Group plc - MarketBeat
Intraday pattern recognizer results for Royalty Pharma plc2025 Year in Review & Free High Return Stock Watch Alerts - Newser
Will Royalty Pharma plc continue its uptrendJuly 2025 Catalysts & Weekly Setup with ROI Potential - Newser
What technical models suggest about Royalty Pharma plc’s comebackJuly 2025 Breakouts & High Yield Equity Trading Tips - Newser
What does recent volatility data suggest for Royalty Pharma plcPortfolio Performance Report & Long Hold Capital Preservation Plans - Newser
Royalty Pharma secures $950 million royalty stake in Amgen’s Imdelltra - PharmiWeb.com
Raymond James Financial Inc. Boosts Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion - ADVFN Brasil
Short interest data insights for Royalty Pharma plcWatch List & Weekly Breakout Stock Alerts - Newser
Will Royalty Pharma plc price bounce be sustainablePortfolio Value Summary & Accurate Trade Setup Notifications - Newser
Royalty Pharma plc stock prediction for this weekJuly 2025 Big Picture & Weekly High Return Stock Forecasts - Newser
Royalty Pharma (RPRX) Acquires US$885 Million Royalty Interest In Amgen's Imdelltra - Yahoo Finance
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up - Benzinga
Royalty Pharma Acquires Imdelltra Royalty Rights from BeOne Medicines for Up to $950M - AInvest
Is Royalty Pharma plc a candidate for recovery playEarnings Recap Report & Consistent Return Strategy Ideas - Newser
Royalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen - TipRanks
Royalty Pharma to Acquire Royalty Interest in Amgen?s Imdelltra for up to $950 Million - MarketScreener
Will Royalty Pharma plc stock recover after recent dropQuarterly Profit Summary & Real-Time Buy Zone Alerts - Newser
Royalty Pharma To Acquire Royalty Interest in Amgen’s Imdelltra For $950 Million - citybiz
Royalty Pharma's Unit Signs Royalty Purchase Agreement with BeiGene - AInvest
Royalty Pharma acquires Imdelltra royalty interest for $885 million By Investing.com - Investing.com South Africa
Beigene and unit sign royalty purchase agreement with Royalty Pharma plc's unit - MarketScreener
BeOne Sells Cancer Drug Royalty Rights to Royalty Pharma - MarketScreener
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug - Yahoo Finance
Royalty Pharma Acquires Royalty Interest In Imdelltra From BeOne - Nasdaq
Royalty Pharma acquires Imdelltra royalty interest for $885 million - Investing.com
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million - MarketScreener
Royalty Pharma Acquires Royalty Interest in Amgen's Imdelltra for Up to $950 Million - AInvest
$2.8B Peak Sales Potential: Royalty Pharma Acquires Rights to Breakthrough Lung Cancer Drug Imdelltra - Stock Titan
Credit Agricole S A Purchases 118,184 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc building a consolidation baseEarnings Overview Report & Fast Momentum Stock Entry Tips - Newser
State of New Jersey Common Pension Fund D Sells 20,498 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Candlestick signals on Royalty Pharma plc stock todayEarnings Risk Summary & Safe Entry Zone Tips - Newser
Royalty Pharma PLC $RPRX Shares Acquired by LPL Financial LLC - MarketBeat
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):